Immix biopharma advances car-t nxc-201 to expansion cohort dose level in u.s. al amyloidosis trial nexicart-2

Now dosing at dose expansion level of 450 million nxc-201 car+t cells. first cohort at 150 million car+t cells already successfully completed each of these two doses have produced complete responses in prior clinical studies lead site memorial sloan kettering cancer center (mskcc); 4 disclosed clinical sites so far nxc-201 is the only one-time car-t treatment option being studied for relapsed/refractory al amyloidosis in u.s. clinical trials al amyloidosis, a disorder of plasma cells that leads to progressive damage to the heart, kidney and liver, affects approximately 33,000 patients in the u.s. los angeles, ca, oct. 02, 2024 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us”, “immx”) (nasdaq: immx), a clinical-stage biopharmaceutical company developing cell therapies for al amyloidosis and select immune-mediated diseases, today announced advances in the nexicart-2 clinical study of its car-t nxc-201 for relapsed/refractory al amyloidosis, a plasma cell disorder that leads to progressive damage to the heart, kidney and liver, which currently affects approximately 33,000 patients in the u.s. immix biopharma's sterically-optimized car-t nxc-201 is the only one-time car-t treatment option being studied for relapsed/refractory al amyloidosis in u.s. clinical trials.
CAR Ratings Summary
CAR Quant Ranking